AKRO

Akero Therapeutics, Inc. is a biotechnology company headquartered in South San Francisco, California, focused on developing innovative therapies for nonalcoholic steatohepatitis (NASH), a significant liver disease linked to cardiometabolic health complications. Leveraging its proprietary drug development platform, Akero aims to restore metabolic balance and improve patient outcomes, establishing itself as a frontrunner in tackling the unmet medical needs associated with metabolic disorders. The company's dedication to advancing therapeutic solutions highlights its strategic focus on enhancing the quality of care for patients suffering from chronic liver conditions, positioning it favorably within the biotechnology sector.